The GLP-1 Pipeline Is Exploding. Here's What's Coming Next
Semaglutide and tirzepatide changed the conversation around metabolic health. But they're not the end of the story — they're the beginning. The next generation of incretin-based peptides is already in trials, and the targets are getting more ambitious.
What's In Development
The current pipeline includes peptides that go beyond single-receptor activity:
- Retatrutide — triple agonist (GLP-1, GIP, glucagon) showing significant weight loss in trials
- CagriSema — combines a GLP-1 with an amylin analogue
- Survodutide — dual GLP-1 / glucagon agonist
- Oral GLP-1 formulations — removing the injection barrier entirely
Why It Matters
Each new mechanism unlocks different effect profiles. Triple agonists may produce stronger weight loss with different side-effect curves. Oral formulations could expand access dramatically. Multi-receptor peptides are starting to look less like weight-loss drugs and more like metabolic recalibration tools.
The Bigger Trend
GLP-1s are doing for peptides what insulin did for hormone therapy: legitimizing the entire category. Every successful trial expands research budgets, attracts talent, and increases regulatory familiarity with peptide-based therapeutics.
Interactive
Run the numbers yourself
Open the full Peptide Calculator — concentration, dilution, and syringe draw, instant.
Open calculatorMore options means more decisions. Protocol helps you keep track of dose, timing, and effect across every protocol you run.
Coming SoonThis content is for educational purposes only and does not constitute medical advice.
Continue reading
Why Peptides Are Suddenly Everywhere
Peptides have moved from niche biohacker forums to TikTok, longevity podcasts, and mainstream wellness. Here's what's actually driving the surge.
Trends / NewsRFK Jr. Is Pushing to Expand Peptide Access. Here's Where It Stands
HHS Secretary Robert F. Kennedy Jr. has publicly backed loosening restrictions on previously restricted peptides. Here's what he's proposing.
Trends / NewsThe FDA Is Reconsidering Peptides. Here's What That Means
The FDA is reviewing whether to allow compounding of certain peptides again. Here's what's actually on the table — and what isn't.